Jerome Milton, Inc. v. Federal Trade Commission

734 F. Supp. 1416, 1990 U.S. Dist. LEXIS 2736
CourtDistrict Court, N.D. Illinois
DecidedMarch 12, 1990
Docket89 C 3941
StatusPublished
Cited by1 cases

This text of 734 F. Supp. 1416 (Jerome Milton, Inc. v. Federal Trade Commission) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jerome Milton, Inc. v. Federal Trade Commission, 734 F. Supp. 1416, 1990 U.S. Dist. LEXIS 2736 (N.D. Ill. 1990).

Opinion

MEMORANDUM OPINION AND ORDER

ROVNER, District Judge.

I. INTRODUCTION

Plaintiff Jerome Milton, Inc., a corporation engaged in the promotion and sale of health care products, and its president, Jerome Milton Schulman, brought this lawsuit to challenge certain conduct by the Federal Trade Commission (the “FTC” or “Commission”). Pending is the FTC’s motion for summary judgment on the grounds that there has been no final agency action and, alternatively, that the dispute is not ripe for review. The Court agrees with the FTC that the letter is not final agency action and therefore dismisses the case for want of jurisdiction.

II. FACTS

The essential facts relevant to the pending motion are not in dispute. Plaintiffs manufacture and sell a product called Shane toothpaste. On September 24, 1984, the FTC issued an administrative complaint against plaintiffs, alleging that they had violated §§ 5 and 12 of the FTC Act, 15 U.S.C. §§ 45, 52. 1 The administrative complaint alleged that plaintiffs unfairly and deceptively represented, directly or by implication, that they had a reasonable basis for the following representations in their advertising of Shane toothpaste:

a. the use of Shane will cure, or alleviate the symptoms of, canker sores (recurrent aphthous stomatitis), cold sores (herpes simplex type I lesions), and the gum problems associated with gingivitis and periodontitis;
b. Shane is superior to other toothpastes in reducing or eliminating plaque; and
c. the use of Shane will lessen the sensitivity of the teeth to hot and cold substances.

(Complaint, Ex. A at ¶ 5.)

In accordance with § 5(b) of the FTC Act, 2 the administrative complaint was accompanied by a notice stating that a hearing would be held on November 5, 1984, and that the FTC had reason to believe that an order should issue that plaintiffs cease and desist making the representations at issue,

unless at the time of making such representation, respondents possess and rely upon competent and reliable evidence substantiating the representation. For purposes of this order, “competent and reliable evidence” shall mean a test, analysis, research project, or study in *1418 which the evidence has been objectively obtained and evaluated by persons qualified to do so, using procedures generally accepted in the relevant profession to yield accurate results.

(Complaint, Ex. A at 5.)

After three years of litigation before the FTC which plaintiffs describe as “financially exhaustive” (Complaint, ¶ 10), and during which plaintiffs voluntarily refrained from advertising Shane toothpaste, plaintiffs entered into settlement negotiations with the FTC. A proposed consent order was agreed to by plaintiffs and counsel for the FTC which contained the precise substantiation language of the order which the FTC had originally sought. On April 9, 1987, the Commission rejected this consent order. 3

A consent order was eventually reached which the Commission approved on October 26, 1987. Plaintiffs were ordered, in part, to:

cease and desist from representing, directly or by implication, that any such [oral hygiene] product:
a. cures or alleviates the symptoms of canker sores (recurrent aphthous stomatitis) or cold sores (herpes simplex type I lesions);
b. reduces the sensitivity of teeth to hot and cold substances;
c. is useful in the diagnosis, cure, mitigation, treatment, or prevention of disease in man;
d. reduces plaque more effectively than any other toothpaste or oral hygiene product; or
e. cures or alleviates the gum problems associated with gingivitis or periodontitis,
unless at the time of making such representation, respondents possess and rely upon competent and reliable evidence that substantiates the representation.
For purposes of paragraphs a and b, above, “competent and reliable evidence” shall include at least one adequate and well-controlled, double-blind clinical study that conforms to accepted designs and protocols and is conducted by persons qualified by training and experience to do so;
For purposes of paragraphs d and e, above, “competent and reliable evidence” shall include at least two adequate and well-controlled, double-blind clinical studies that conform to accepted designs and protocols and are conducted by different persons, independently of each other, with such persons being qualified by training and experience to conduct such studies;
For purposes of paragraph c, above, “competent and reliable evidence” shall mean test(s), analysis(es), research project(s), or study(ies) in which the evidence has been objectively obtained and evaluated by persons qualified to do so, using procedures generally accepted in the relevant profession to yield accurate results.

(Complaint, Ex. D at 2-3, emphasis added.) The final consent order thus retained essentially the same requirements for substantiation of the certain claims, including the sensitivity claims which are central to this case, but increased the requirements for substantiation of other claims. As part of the settlement, plaintiffs also agreed to file a compliance report within 60 days. (Def. Ex. 1.)

Meanwhile, in July of 1986, plaintiffs had commissioned the University of Iowa to conduct a clinical study concerning Shane’s ability to reduce the sensitivity of teeth to temperature and pressure. Plaintiffs received the results of this study in March, *1419 1987. The study concluded that “Shane toothpaste is effective in reducing dental sensitivity to both cold and pressure when used regularly as an adjunct to daily oral hygiene procedures.” 4

On December 18, 1987, plaintiffs submitted their written compliance report to the FTC. In that report, they stated that they had not advertised Shane toothpaste. They also submitted with the report a copy of the University of Iowa study.

From January through April, 1988, several telephone conversations took place between Mr. Schulman and Rose Toufexis, a Commission staff attorney. During these conversations, Mr. Schulman stated an intent to begin advertising that Shane could reduce dental sensitivity. Ms. Toufexis stated that the University of Iowa study had been submitted to two independent experts for their evaluation and that they had concluded that the study did not constitute competent and reliable evidence that Shane toothpaste could reduce dental sensitivity. Mr. Schulman requested that Ms.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Boyd v. Glickman
12 F. Supp. 2d 1261 (M.D. Alabama, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
734 F. Supp. 1416, 1990 U.S. Dist. LEXIS 2736, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jerome-milton-inc-v-federal-trade-commission-ilnd-1990.